OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
87 hedge funds and large institutions have $175M invested in OncoMed Pharmaceuticals, Inc. in 2015 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 37 increasing their positions, 18 reducing their positions, and 7 closing their positions.
106% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 18
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
5% more funds holding
Funds holding: 83 → 87 (+4)
26% less capital invested
Capital invested by funds: $235M → $175M (-$60.1M)
41% less call options, than puts
Call options by funds: $1.86M | Put options by funds: $3.13M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
+$6.22M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$6.19M |
| 3 |
Millennium Management
New York
|
+$2.41M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$2.23M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$1.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$25.3M |
| 2 |
JP Morgan Chase
New York
|
-$2.53M |
| 3 |
Mitsubishi UFJ Asset Management
Tokyo,
Japan
|
-$1.57M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$1.32M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$687K |
OMED Hedge Fund Activity: Q3 2015 in Review
87 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q3 2015, worth a combined $175M — down 26% from $235M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new OMED positions and 7 closed out — a net gain of 4 holders — while 37 added to existing stakes and 18 trimmed.
The largest buyer was Disciplined Growth Investors, opening a new position worth an estimated $6.22M. The largest seller was Sectoral Asset Management, cutting an estimated $25.3M.
- 87 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q3 2015, up from 83 in Q2 2015.
- Funds reported $175M of OncoMed Pharmaceuticals, Inc. stock for Q3 2015, down 26% quarter-over-quarter.
- 11 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q3 2015 and 7 closed out, a net change of +4 holders.
- The largest OncoMed Pharmaceuticals, Inc. buyer in Q3 2015 was Disciplined Growth Investors, an estimated $6.22M added.
- The largest OncoMed Pharmaceuticals, Inc. seller in Q3 2015 was Sectoral Asset Management, an estimated $25.3M sold.
Based on aggregated 13F filings for Q3 2015.